{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:27:21Z","timestamp":1787923641654,"version":"build-2784847793"},"reference-count":114,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"name":"National Institutes of Health, National Cancer Institute","award":["RT32 CA203703"],"award-info":[{"award-number":["RT32 CA203703"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Male breast cancer (BC) comprises approximately 1% of all BC cases. Although incidence has increased over recent decades, male BC remains understudied, and its management continues to rely on evidence extrapolated from studies focused on female patients. This narrative review synthesizes current knowledge on male BC epidemiology, risk factors, diagnosis, treatment, and male-specific considerations that may impact outcomes. Key risk factors include genetic susceptibility, particularly BRCA2 mutations, and conditions that promote hormonal imbalance and excess estrogen exposure, such as obesity and hepatic dysfunction. Men with BC are typically diagnosed later in life, with more advanced disease, and experience worse outcomes than women. Observational data demonstrate underutilization of guideline-recommended locoregional and systemic therapies across modalities among male patients, and uncertainties persist regarding systemic therapy choice and sequencing. The paucity of male-specific prospective data highlights the need to significantly improve male representation in future BC trials. Rigorous analyses of real-world evidence with careful attention to confounders are needed to better characterize current practice patterns, identify gaps in guideline adherence, and evaluate efficacies of systemic therapies.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag318","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:41:11Z","timestamp":1787398871000},"source":"Crossref","is-referenced-by-count":0,"title":["Male breast cancer: from extrapolated practice to evidence-based care"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3184-9174","authenticated-orcid":false,"given":"Bethina","family":"Liu","sequence":"first","affiliation":[{"name":"Columbia University Irving Medical Center Division of Hematology and Oncology, , New York, NY 10032,","place":["United States"]},{"name":"James J. Peters Bronx Veterans Affairs Medical Center Department of Hematology and Oncology, , Bronx, NY 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-9804","authenticated-orcid":false,"given":"Alissa M","family":"Michel","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center Division of Hematology and Oncology, , New York, NY 10032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9871-4463","authenticated-orcid":false,"given":"Prabhjot S","family":"Mundi","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center Division of Hematology and Oncology, , New York, NY 10032,","place":["United States"]},{"name":"James J. Peters Bronx Veterans Affairs Medical Center Department of Hematology and Oncology, , Bronx, NY 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-4861","authenticated-orcid":false,"given":"Keith M","family":"Sigel","sequence":"additional","affiliation":[{"name":"James J. Peters Bronx Veterans Affairs Medical Center Department of Hematology and Oncology, , Bronx, NY 10468,","place":["United States"]},{"name":"Icahn School of Medicine at Mount Sinai Department of Medicine, , New York, NY 10029,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-0330","authenticated-orcid":false,"given":"Susan E","family":"Bates","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center Division of Hematology and Oncology, , New York, NY 10032,","place":["United States"]},{"name":"James J. Peters Bronx Veterans Affairs Medical Center Department of Hematology and Oncology, , Bronx, NY 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-231X","authenticated-orcid":false,"given":"Yeun-Hee A","family":"Park","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center Division of Hematology and Oncology, , New York, NY 10032,","place":["United States"]},{"name":"James J. Peters Bronx Veterans Affairs Medical Center Department of Hematology and Oncology, , Bronx, NY 10468,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"2026082719061593800_oyag318-B1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1186\/s12885-025-14681-0","article-title":"Global, regional, and national burden of male breast cancer and predictions in the next 30 years: a systematic analysis of the global burden of disease study 2021","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"2026082719061593800_oyag318-B2","doi-asserted-by":"publisher","first-page":"1734049","DOI":"10.1155\/2022\/1734049","article-title":"Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment","volume":"2022","author":"Zheng","year":"2022","journal-title":"J Oncol"},{"key":"2026082719061593800_oyag318-B3","volume-title":"Key Statistics for Breast Cancer in Men","author":"American Cancer Society","year":"2026"},{"key":"2026082719061593800_oyag318-B4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cncr.32472","article-title":"Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century","volume":"126","author":"Yadav","year":"2020","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026082719061593800_oyag318-B6","volume-title":"Breast Cancer Facts & Figures 2024-2025","author":"American Cancer Society","year":"2024"},{"key":"2026082719061593800_oyag318-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-015-0487-4","article-title":"The epidemiology of male breast cancer","volume":"18","author":"Ferzoco","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2026082719061593800_oyag318-B8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jamaoncol.2019.2803","article-title":"Overall mortality after diagnosis of breast cancer in men vs women","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026082719061593800_oyag318-B9","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 4.2026","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"2026082719061593800_oyag318-B10","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2026082719061593800_oyag318-B11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026082719061593800_oyag318-B12","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients","volume":"23","author":"Sun","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026082719061593800_oyag318-B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jmg.38.3.159","article-title":"Male breast cancer in Cowden syndrome patients with germline PTEN mutations","volume":"38","author":"Fackenthal","year":"2001","journal-title":"J Med Genet"},{"key":"2026082719061593800_oyag318-B14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026082719061593800_oyag318-B15","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1200\/JCO.2014.59.1602","article-title":"Prediagnostic sex steroid hormones in relation to male breast cancer risk","volume":"33","author":"Brinton","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026082719061593800_oyag318-B16","first-page":"269","article-title":"Risk factors for male breast cancer (United States)","volume":"9","author":"Hsing","year":"1998","journal-title":"Cancer Causes Control"},{"key":"2026082719061593800_oyag318-B17","doi-asserted-by":"publisher","first-page":"djt465","DOI":"10.1093\/jnci\/djt465","article-title":"Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results","volume":"106","author":"Brinton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026082719061593800_oyag318-B18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1572-0241.1998.00231.x","article-title":"Risk of breast cancer in men with liver cirrhosis","volume":"93","author":"S\u00f8rensen","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2026082719061593800_oyag318-B19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/1055-9965.EPI-07-0761","article-title":"Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer","volume":"17","author":"Rock","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"2026082719061593800_oyag318-B20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12603-016-0698-x","article-title":"Effect of lifestyle intervention on the hormonal profile of frail, obese older men","volume":"20","author":"Armamento-Villareal","year":"2016","journal-title":"J Nutr Health Aging"},{"key":"2026082719061593800_oyag318-B21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pros.70074","article-title":"Factors associated with male breast cancer incidence among prostate cancer survivors: real world evidence from veterans affairs national prostate cancer data core","volume":"86","author":"Whyne","year":"2026","journal-title":"Prostate"},{"key":"2026082719061593800_oyag318-B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12020-019-01850-y","article-title":"Relative hyperestrogenism in Klinefelter syndrome: results from a meta-analysis","volume":"64","author":"Santi","year":"2019","journal-title":"Endocrine"},{"key":"2026082719061593800_oyag318-B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2407-2-26","article-title":"Male gynecomastia and risk for malignant tumours\u2014a cohort study","volume":"2","author":"Olsson","year":"2002","journal-title":"BMC Cancer"},{"key":"2026082719061593800_oyag318-B24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/1055-9965.EPI-14-1009","article-title":"Tobacco and alcohol in relation to male breast cancer: an analysis of the male breast cancer pooling project consortium","volume":"24","author":"Cook","year":"2015","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"2026082719061593800_oyag318-B25","first-page":"571","article-title":"Alcohol drinking may increase risk of breast cancer in men: a European population-based case-control study","volume":"15","author":"Gu\u00e9nel","year":"2004","journal-title":"Cancer Causes Control"},{"key":"2026082719061593800_oyag318-B26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.32604\/or.2025.058790","article-title":"Comprehensive review of male breast cancer: understanding a rare condition","volume":"33","author":"Jamil","year":"2025","journal-title":"Oncol Res"},{"key":"2026082719061593800_oyag318-B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2022.01.001","article-title":"Male breast cancer after childhood cancer: systematic review and analyses in the PanCareSurFup cohort","volume":"165","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026082719061593800_oyag318-B28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"2026082719061593800_oyag318-B29","doi-asserted-by":"publisher","first-page":"S578","DOI":"10.1016\/j.jacr.2025.08.040","article-title":"ACR appropriateness criteria\u00ae male breast cancer screening","volume":"22","author":"Freer","year":"2025","journal-title":"J Am Coll Radiol"},{"key":"2026082719061593800_oyag318-B30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer: ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026082719061593800_oyag318-B31","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B32","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1016\/j.jacr.2018.09.017","article-title":"Expert panel on breast imaging: ACR appropriateness criteria\u00ae evaluation of the symptomatic male breast","volume":"15","author":"Niell","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"2026082719061593800_oyag318-B33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinimag.2019.11.005","article-title":"Image-based screening for men at high risk for breast cancer: benefits and drawbacks","volume":"60","author":"Woods","year":"2020","journal-title":"Clin Imaging"},{"key":"2026082719061593800_oyag318-B34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-019-05312-x","article-title":"Is core needle biopsy effective at diagnosing male breast lesions?","volume":"177","author":"Yang","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026082719061593800_oyag318-B35","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2026","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"2026082719061593800_oyag318-B36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2009.23.8162","article-title":"Male breast cancer: a population-based comparison with female breast cancer","volume":"28","author":"Anderson","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026082719061593800_oyag318-B37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","article-title":"Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG international male breast cancer program","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2026082719061593800_oyag318-B38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/apm.13068","article-title":"Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort","volume":"128","author":"Christensen","year":"2020","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"2026082719061593800_oyag318-B39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/modpathol.2017.129","article-title":"Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes","volume":"31","author":"S\u00e1nchez-Mu\u00f1oz","year":"2018","journal-title":"Mod Pathol"},{"key":"2026082719061593800_oyag318-B40","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2026082719061593800_oyag318-B41","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","article-title":"Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies","volume":"39","author":"Prat","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026082719061593800_oyag318-B42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1200\/JCO.2021.39.15_suppl.539","article-title":"Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: comparative analysis to a female cohort (FBC) and therapeutic considerations","volume":"39","author":"Kadamkulam Syriac","year":"2021","journal-title":"JCO"},{"key":"2026082719061593800_oyag318-B43","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-15-2840","article-title":"The genomic landscape of male breast cancers","volume":"22","author":"Piscuoglio","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026082719061593800_oyag318-B44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2026082719061593800_oyag318-B45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"2026082719061593800_oyag318-B46","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"De Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"2026082719061593800_oyag318-B47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026082719061593800_oyag318-B48","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026082719061593800_oyag318-B49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S1470-2045(25)00400-0","article-title":"Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis","volume":"26","author":"Black","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026082719061593800_oyag318-B50","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet"},{"key":"2026082719061593800_oyag318-B51","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/mc.23461","article-title":"Divergence of mutational signatures in association with breast cancer subtype","volume":"61","author":"Perry","year":"2022","journal-title":"Mol Carcinog"},{"key":"2026082719061593800_oyag318-B52","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.modpat.2024.100452","article-title":"Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets","volume":"37","author":"Al Assaad","year":"2024","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"key":"2026082719061593800_oyag318-B53","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00000658-199205000-00007","article-title":"Current management of male breast cancer. A review of 104 cases","volume":"215","author":"Borgen","year":"1992","journal-title":"Ann Surg"},{"key":"2026082719061593800_oyag318-B54","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/cam4.2953","article-title":"Delayed presentation, diagnosis, and psychosocial aspects of male breast cancer","volume":"9","author":"Co","year":"2020","journal-title":"Cancer Med"},{"key":"2026082719061593800_oyag318-B55","doi-asserted-by":"publisher","first-page":"e059669","DOI":"10.1136\/bmjopen-2021-059669","article-title":"Diagnostic pathways for breast cancer in 10 international cancer benchmarking partnership (ICBP) jurisdictions: an international comparative cohort study based on questionnaire and registry data","volume":"12","author":"Vedsted","year":"2022","journal-title":"BMJ Open"},{"key":"2026082719061593800_oyag318-B56","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1245\/s10434-012-2479-z","article-title":"Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the national cancer data base","volume":"19","author":"Greif","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2026082719061593800_oyag318-B57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.breast.2020.08.010","article-title":"Epidemiology of male breast cancer","volume":"54","author":"Konduri","year":"2020","journal-title":"Breast"},{"key":"2026082719061593800_oyag318-B58","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/00031348231212588","article-title":"Is there a survival difference between male and female breast cancer subtypes according to the prognostic staging system? A population-based cohort study","volume":"90","author":"Sanli","year":"2024","journal-title":"Am Surg"},{"key":"2026082719061593800_oyag318-B59","doi-asserted-by":"publisher","first-page":"104556","DOI":"10.1016\/j.breast.2025.104556","article-title":"Long-term survival outcomes of male breast cancer: the propensity score matching analysis of nationwide registry database","volume":"83","author":"Choi","year":"2025","journal-title":"Breast"},{"key":"2026082719061593800_oyag318-B60","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B61","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/s0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet Lond Engl"},{"key":"2026082719061593800_oyag318-B62","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B63","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B64","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B66","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026082719061593800_oyag318-B68","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026082719061593800_oyag318-B69","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026082719061593800_oyag318-B70","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B71","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026082719061593800_oyag318-B73","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"2026082719061593800_oyag318-B74","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: Results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026082719061593800_oyag318-B75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B76","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B77","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"2026082719061593800_oyag318-B78","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B79","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B80","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt Andrew","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B82","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082719061593800_oyag318-B83","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/bjs\/znab279","article-title":"Treatment of male breast cancer: meta-analysis of real-world evidence","volume":"108","author":"Lin","year":"2021","journal-title":"Br J Surg"},{"key":"2026082719061593800_oyag318-B84","doi-asserted-by":"publisher","first-page":"103703","DOI":"10.1016\/j.breast.2024.103703","article-title":"Accuracy of sentinel lymph node biopsy in male breast cancer: systematic review and meta-analysis","volume":"75","author":"Parpex","year":"2024","journal-title":"Breast Edinb Scotl"},{"key":"2026082719061593800_oyag318-B85","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1245\/s10434-023-13475-7","article-title":"Axillary lymph node dissection is associated with improved survival among men with invasive breast cancer and sentinel node metastasis","volume":"30","author":"Chung","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026082719061593800_oyag318-B86","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1245\/s10434-025-18501-4","article-title":"Axillary management trends and survival in men undergoing mastectomy with positive sentinel nodes","volume":"33","author":"Fish","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"2026082719061593800_oyag318-B87","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"2026082719061593800_oyag318-B88","doi-asserted-by":"publisher","first-page":"104537","DOI":"10.1016\/j.critrevonc.2024.104537","article-title":"The role of radiation therapy in the multidisciplinary management of male breast cancer: a systematic review and meta-analysis on behalf of the clinical oncology breast cancer group (COBCG)","volume":"204","author":"Colciago","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026082719061593800_oyag318-B89","doi-asserted-by":"publisher","first-page":"1178223418770687","DOI":"10.1177\/1178223418770687","article-title":"Clinicopathologic features and radiation therapy utilization in patients with male breast cancer: a national cancer database study","volume":"12","author":"Weir","year":"2018","journal-title":"Breast Cancer Basic Clin Res"},{"key":"2026082719061593800_oyag318-B90","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"2026082719061593800_oyag318-B91","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1002\/cncr.25153","article-title":"Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival","volume":"116","author":"Harlan","year":"2010","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B92","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamaoncol.2020.7442","article-title":"Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial","volume":"7","author":"Reinisch","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026082719061593800_oyag318-B93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41416-020-0857-z","article-title":"Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis","volume":"123","author":"Eggemann","year":"2020","journal-title":"Br J Cancer"},{"key":"2026082719061593800_oyag318-B94","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-012-2355-3","article-title":"Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients","volume":"137","author":"Eggemann","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2026082719061593800_oyag318-B95","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00432-017-2539-7","article-title":"Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer","volume":"144","author":"Eggemann","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026082719061593800_oyag318-B96","doi-asserted-by":"publisher","first-page":"e181114","DOI":"10.1001\/jamaoncol.2018.1114","article-title":"Use and effectiveness of adjuvant endocrine therapy for hormone receptor\u2013positive breast cancer in men","volume":"4","author":"Venigalla","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026082719061593800_oyag318-B97","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-015-0147-z","article-title":"Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis","volume":"8","author":"Di Lauro","year":"2015","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"2026082719061593800_oyag318-B98","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/bjc.2013.255","article-title":"Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series","volume":"108","author":"Zagouri","year":"2013","journal-title":"Br J Cancer"},{"key":"2026082719061593800_oyag318-B99","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-014-3240-z","article-title":"Fulvestrant and male breast cancer: a pooled analysis","volume":"149","author":"Zagouri","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2026082719061593800_oyag318-B100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/cncr.33899","article-title":"Adjuvant tamoxifen adherence in men with early-stage breast cancer","volume":"128","author":"Oke","year":"2022","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B101","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.32829","article-title":"The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: a population-based observational study","volume":"126 Suppl 16","author":"Pan","year":"2020","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B102","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1200\/JCO.2017.76.8861","article-title":"Molecular characterization and mortality from breast cancer in men","volume":"36","author":"Massarweh","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026082719061593800_oyag318-B103","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/1078-0432.CCR-19-2424","article-title":"Sex disparity observed for oncotype DX breast recurrence score in predicting mortality among patients with early stage ER-positive breast cancer","volume":"26","author":"Wang","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026082719061593800_oyag318-B104","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10549-026-07978-6","article-title":"The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer","volume":"217","author":"Gaba","year":"2026","journal-title":"Breast Cancer Res Treat"},{"key":"2026082719061593800_oyag318-B105","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-021-00301-0","article-title":"Evaluation of multiple transcriptomic gene risk signatures in male breast cancer","volume":"7","author":"Bayani","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026082719061593800_oyag318-B106","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/cncr.34448","article-title":"Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer","volume":"128","author":"Leone","year":"2022","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B107","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13046-015-0143-8","article-title":"Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study","volume":"34","author":"Di Lauro","year":"2015","journal-title":"J Exp Clin Cancer Res CR"},{"key":"2026082719061593800_oyag318-B108","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.breast.2022.09.009","article-title":"Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: a multicenter study","volume":"66","author":"Y\u0131ld\u0131r\u0131m","year":"2022","journal-title":"Breast Edinb Scotl"},{"key":"2026082719061593800_oyag318-B109","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/cncr.22589","article-title":"Male breast cancer in the veterans affairs population: a comparative analysis","volume":"109","author":"Nahleh","year":"2007","journal-title":"Cancer"},{"key":"2026082719061593800_oyag318-B110","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1016\/j.clbc.2021.01.013","article-title":"Gender disparity in breast cancer: a veteran population-based comparison","volume":"21","author":"Aggarwal","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"2026082719061593800_oyag318-B111","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.2025.43.16_suppl.538","article-title":"Patterns in male and female breast cancer care: a comparative analysis of stage at presentation, treatment, and survival in the veterans health administration","volume":"43","author":"Naaseh","year":"2025","journal-title":"JCO"},{"key":"2026082719061593800_oyag318-B112","doi-asserted-by":"publisher","first-page":"TPS632","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS632","article-title":"ETHAN: a phase II study comparing different endocrine therapies for male breast cancer","volume":"42","author":"Leone","year":"2024","journal-title":"JCO"},{"key":"2026082719061593800_oyag318-B113","doi-asserted-by":"publisher","first-page":"P5-23-04","DOI":"10.1158\/1538-7445.SABCS17-P5-23-04","article-title":"Abstract P5-23-04: Men with advanced breast cancer (BC): initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor","volume":"78","author":"Elias","year":"2018","journal-title":"Cancer Res"},{"key":"2026082719061593800_oyag318-B114","volume-title":"A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer","author":"SWOG Cancer Research Network","year":"2013"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag318\/70763731\/oyag318.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag318\/70763731\/oyag318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag318\/70763731\/oyag318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:43:29Z","timestamp":1787921009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag318\/8768667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":114,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag318","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag318"}}